Usted buscó: bcrp (Inglés - Estonio)

and bcrp
poolt ja bcrp

bcrp substrates
bcrp substraadid

mechanism: bcrp
mehhanism:

(bcrp inhibition)
(brcr inhibitsioon)

interactions with bcrp
koostoimed bcrp kaudu

(intestinal bcrp inhibition)
(soole bcrp inhibeerimine)

bcrp, mrp2, oat3 and oct1 substrates
bcrp, mrp2, oat3 ja oct1 substraadid

medicinal products transported by bcrp
bcrp poolt transporditavad ravimid

(inhibition of oatp1b and bcrp)
(oatp1b ja bcrp inhibeerimine)

(primarily due to intestinal bcrp inhibition
(peamiselt soole bcrp inhibeerimise ja

dasabuvir is an inhibitor of bcrp in vivo.
dasabuviir on bcrp inhibiitor in vivo.

(primarily due to intestinal bcrp inhibition)
(peamiselt soole bcrp inhibeerimise

(oatp1b1/3, bcrp transporter inhibition)
(oatp1b1/3, bcrp transporteri

bcrp, oatp1b1, oatp1b3 and p-gp substrates
bcrp, oatp1b1, oatp1b3 ja p-gp substraadid

metabolite m-5 is a weak bcrp-substrate.
metaboliit m-5 on nõrk bcrp-substraat.

lapatinib is a substrate for the transport proteins pgp and bcrp.
lapatiniib on transportvalkude pgp ja bcrp substraat.

lapatinib inhibits the transport proteins bcrp and oatp1b1 in vitro.
lapatiniib inhibeerib in vitro transportvalke bcrp ja oatp1b1.

caution is advised when cresemba is given concomitantly with substrates of bcrp.
cresemba samaaegsel manustamisel bcrp substraatidega on soovitatav olla ettevaatlik.

expected due to inhibition of oatp 1b1 and/or bcrp by daclatasvir:
ootuspärane on, et daklatasviiri oatp 1b1 ja/või bcrp inhibeeriva toime tõttu:

based on in vitro studies, osimertinib is a competitive inhibitor of bcrp transporters.
in vitro uuringute alusel on osimertiniib bcrp transporterite konkureeriv inhibiitor.